## Nye legemidler som ikke har markedsføringstillatelse

**For legemidler oppført på listen gjelder retningslinjens vilkår <u>uavhengig av indikasjon for bruken.</u> Oppdatert: 13.06.2019** 

Virkestoff	Indikasjon per nå. (Samt mulig andre indikasjoner i fremtiden.)	Orphan medicinal product (* Se informasjon nederst)	Oppført på listen
Isatuximab	Treatment of patients with multiple	,	
	myeloma (MM	х	jun.19
Deferiprone	Treatment of neurodegeneration with		
	brain iron accumulation (Kun denne		
	indikasjonen)	x	jun.19
Givosiran	Indicated for the treatment of acute		-
	hepatic porphyria in adults and		
	adolescents		jun.19
Luspatercept	Treatment of adult patients with very low-		
	to intermediate-risk myelodysplastic		
	syndromes (MDS)-associated anaemia; -		
	the treatment of adult patients with beta-		
	thalassaemia (β-thalassaemia)-		
	associated anaemia who require RBC		
	transfusions		
		x	jun.19
Glasdegib	Treatment of newly diagnosed de novo		
-	or secondary acute myeloid leukaemia		
		x	jun.19
Treprostinil sodium	Treatment of thromboembolic		-
	pulmonary hypertension (CTEPH) (kun		
	denne spesifikke indikasjonen)	x	mar.19
Methylthioninium chloride	Indicated as an aid for the enhanced		
	visualization and detection of colorectal		
	lesions in adult patients undergoing		
	screening / surveillance colonoscopy for		
	colorectal cancer. An increased detection		
	of colorectal lesions translates into an		
	increase in the adenoma detection rate		
	(ADR). (kun denne spesifikke		
	indikasjonen)		mar.19
Pexidartinib	Treatment of symptomatic tenosynovial		
	giant cell tumor (TGCT), also known as		
	pigmented villonodular synovitis (PVNS)		
	and giant cell tumor of the tendon sheath		
	(GCT-TS), where surgical resection is		
	potentially associated with worsening		
	functional limitation or severe morbidity		
		x	mar.19

Darolutamide	Non-metastatic castration resistant		
	prostate cancer		mar.19
Gliteritinib	Treatment of patients who have relapsed		
	or refractory acute myeloid leukemia		
	(AML) with a FLT3 mutation		
		х	mar.19
Imlifidase	Indicated for desensitization treatment		
	of highly sensitized adult kidney		
	transplant patients with positive		
	crossmatch against an available deceased		
	donor	х	mar.19
Fenfluramine	Treatment of seizures associated with		
	Dravet syndrome in children aged 2 years		
	to 17 years and adults.	х	mar.19
Brolucizumab	Treatment of neovascular (wet) age-		
	related macular degeneration (AMD)		
			mar.19
Upadacitinib	Treatment of moderate to severe active		
opudacitinis	rheumatoid arthritis		feb.19
Gilteritinib	Treatment in adults of FMS-like tyrosine		100.15
Onternando	kinase 3 (FLT3) mutation positive		
	patients with relapsed or refractory acute		
	myeloid leukemia (AML).		fab 10
haaidanih		Х	feb.19
Ivosidenib	Treatment of adult patients ( $\geq$ 18 years		
	old) with relapsed or refractory acute		
	myeloid leukaemia (AML) with an		
	isocitrate dehydrogenase-1 (IDH1) R132		
	mutation	Х	feb.19
Tagraxofusp	Treatment of adult patients with blastic		
	plasmacytoid dendritic cell neoplasm		
	(BPDCN)	х	feb.19
Diclofenamide	Treatment of periodic paralysis		feb.19
Selinexor	Treatment of patients with relapsed		
	refractory multiple myeloma (RRMM)		
		х	jan.19
Polatuzumab vedotin	Treatment of mature B cell lymphomas		, ,
			ian 10
Cafidaracal	Treatment of infections caused by		jan.19
Cefiderocol	Treatment of infections caused by		
	carbapenem-resistant Gram-negative		
	bacteria in adult patients with limited		
	treatment options. Treatment of		
	infections caused by aerobic Gram-		
	negative bacteria in adult patients with		
	limited treatment options		
			jan.19

Entrectinib	Treatment of adult and paediatric		
	patients with neurotrophic tyrosine		
	receptor kinase (NTRK) fusion-positive		
	locally advanced or metastatic solid		
	tumours.Treatment of patients with		
	ROS1-positive, advanced non-small cell		
	lung cancer (NSCLC)		
			iau 10
Osilodrostat	Treatment of Cushing's syndrome	x	jan.19 jan.19
Imipenem/ Cilastatin/	Treatment of bacterial infections due to	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Janizo
Relebactam	gram-negative microorganisms		jan.19
			Jan.19
Onasemnogene abeparvovec	Treatment of spinal muscular atroophy	, v	nov 19
	(SMA)	Х	nov.18
Quizartinib	Treatment for acute myeloid leukaemia	, v	nov 19
Plazomicin	Treatment of Complicated urinary tract	Х	nov.18
	infection (cUTI), including pyelonephritis;		
	treatment of Bloodstream infection (BSI);		
	treatment of infections due to		
	Enterobacteriaceae		
			nov.18
Depatuximab mafodotin	Treatment of glioblastoma (GBM)		nov.18
Alpelisib	Treatment of with hormone receptor		
	(HR)-positive, human		
	epidermal growth factor receptor 2		
	(HER2)-negative, advanced breast cancer		
	with a PIK3CA mutation		
	in combination with fulvestrant after		
	disease progression following an		
	endocrine-based regimen		okt.18
Omadacycline tosylate	Treatment of community-acquired		
	bacterial pneumonia (CABP) and acute		
	bacterial skin and skin structure		okt.18
Siponimod	Treatment of secondary progressive		
	multiple sclerosis (SPMS)		okt.18
autologous cd34+ cell enriched	Treatment of transfusion-dependent β-		
population that contains	thalassaemia (TDT)		
hematopoietic stem cells			
transduced with lentiglobin			
bb305 lentiviral vector encoding	2		
the beta-a-t87q-globin gene			
		х	okt.18
Siponimod	Indicated for the treatment of		
	thrombocytopenia		okt.18
Dolutegravir / lamivudine	Treatment of Human Immunodeficiency		
	Virus type 1 (HIV-1)		
			okt.18

Adeno-associated viral vector	Treatment of paediatric patients		
serotype 9 containing the	diagnosed with spinal muscular atrophy		
human SMN gene (AVXS-101)	Type 1		okt.18
	Treatment of non-neurological		
	manifestations of acid sphingomyelinase		
Olipudase alfa	deficiency		okt.18
	Treatment of adult and paediatric		
	patients with locally advanced or		
Larotrectinib	metastatic solid tumours	х	sep.18
	Treatment of adults infected with HIV-1		
	resistant to at least 1 agent in 3 different		
Ibalizumab	classes		sep.18
	Treatment of adult patients with		
	paroxysmal nocturnal hemoglobinuria		
Ravulizumab	(PNH)	х	aug.18
	Reduction of renal radiation exposure		
	during Peptide-Receptor Radionuclide		
L-lysine hydrochloride / l-	Therapy (PRRT) with lutetium (177Lu)		
arginine hydrochloride	oxodotreotide		jul.18
	Treatment of acute myeloid leukaemia		
Enasidenib	(AML)	х	jul.18
	Treatment of hypotension in adults with		
	distributive or vasodilatory shock who		
	remain hypotensive despite fluid and		
	vasopressor therapy		
Angiotensin ii			jul.18
	Treatment of Acute Bacterial Skin and		
	Skin Structure Infection (ABSSSI) in adults		
Delafloxacin			jun.18
	Monotherapy, indicated for the		
	treatment of patients with metastatic		
Cemiplimab	cutaneous squamous cell carcinoma		mai.18
	Treatment and prophylaxis of bleeding in		
	patients with haemophilia A		
Turoctocog alfa pegol		Х	mai.18
Glutamine	Treatment of sickle cell disease		mar.18
Trientine dihydrochloride	Treatment of Wilson's disease	X	mar.18
Selumetinib	Neurofibromatosis		mar.18
Avapritinib	Treatment of mastocytosis and GIST Treatment of breastcancer		mar.18
Ipatasertib			mar.18
	Treatment of BRCA 1, BRCA 2, BARD1		
Veliparib	and/orr PALB2 mutated cancer		mar.18
	Treatment of breastcancer and		
Talazoparib	prostatecancer		mar.18
Copanlisib	Treatment of non-hodgkin lymphoma		mar.18
	Treatment of acute myeloid leukaemia		
Enasidenib			mar.18
Acalabrutinib	Treatment of mantel cell lymphoma		mar.18

	Conditioning treatment prior to		
	allogeneic haematopoietic stem cell		
	transplantation (alloHSCT)		
Treosulfan	transplantation (alloHSCT)	х	mar.18
	Adjunctive therapy of seizures associated		
	with Lennox-Gastaut syndrome (LGS) or		
	Dravet syndrome (DS),		
Cannabidiol		х	mar.18
	Avatrombopag is indicated for the		
	treatment of thrombocytopenia in adult		
	patients with chronic liver disease who		
	are scheduled to undergo a procedure.		
Avatrompag Maleat			mar.18
Rovalpituzumab tesirine	Small cell lung cancer (SCLC)		jan.18
Edaravone	Amyotrophic lateral sclerosis (ALS)		jan.18
Romosozumab	Treatment of osteoporosis		jan.18
	Treatment of acute radiation syndrome		
Entolimod		х	nov.17
	Temporary improvement in the		
	appearance of moderate to severe		
Botulinum toxin type a	vertical lines between the eyebrows		jul.17
	Intended for the treatment of adult		
	patients with diffuse large B-cell		
	lymphoma (DLBCL) who have not		
Autologous T cells transduced	responded to their prior therapy, or have		
with retroviral vector encoding	had disease progression after autologous		
an anti-CD19 CD28/CD3-zeta	stem cell transplant (ASCT)		
chimeric antigen receptor		х	jun.17
* Se informasjon om COMP			
(komiteen for legemidler mot			
sjeldne sykdommer) på			
www.legemiddelverket.no			